{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=RAS%28ON%29+Inhibitors",
    "query": {
      "intervention": "RAS(ON) Inhibitors"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 13,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=RAS%28ON%29+Inhibitors&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-10-27T16:52:23.740Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02671435",
      "title": "A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Solid Tumors"
      ],
      "interventions": [
        {
          "name": "Monalizumab",
          "type": "DRUG"
        },
        {
          "name": "Durvalumab",
          "type": "DRUG"
        },
        {
          "name": "Cetuximab",
          "type": "DRUG"
        },
        {
          "name": "mFOLFOX6",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "MedImmune LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 383,
      "start_date": "2016-02-22",
      "completion_date": "2027-07-30",
      "has_results": true,
      "last_update_posted_date": "2026-06-15",
      "last_synced_at": "2026-10-27T16:52:23.740Z",
      "location_count": 22,
      "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Duarte, California + 19 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02671435"
    },
    {
      "nct_id": "NCT02735707",
      "title": "Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Community-acquired Pneumonia, Influenza, COVID-19"
      ],
      "interventions": [
        {
          "name": "Ceftriaxone",
          "type": "DRUG"
        },
        {
          "name": "Moxifloxacin or Levofloxacin",
          "type": "DRUG"
        },
        {
          "name": "Piperacillin-tazobactam",
          "type": "DRUG"
        },
        {
          "name": "Ceftaroline",
          "type": "DRUG"
        },
        {
          "name": "Amoxicillin-clavulanate",
          "type": "DRUG"
        },
        {
          "name": "Standard course macrolide",
          "type": "DRUG"
        },
        {
          "name": "Extended course macrolide",
          "type": "DRUG"
        },
        {
          "name": "No systemic corticosteroid",
          "type": "OTHER"
        },
        {
          "name": "Fixed-duration Hydrocortisone",
          "type": "DRUG"
        },
        {
          "name": "Shock-dependent hydrocortisone",
          "type": "DRUG"
        },
        {
          "name": "Fixed-duration higher dose Hydrocortisone",
          "type": "DRUG"
        },
        {
          "name": "No antiviral agent for influenza",
          "type": "OTHER"
        },
        {
          "name": "Five-days oseltamivir",
          "type": "DRUG"
        },
        {
          "name": "Ten-days oseltamivir",
          "type": "DRUG"
        },
        {
          "name": "No antiviral agent for COVID-19",
          "type": "OTHER"
        },
        {
          "name": "Lopinavir / Ritonavir",
          "type": "DRUG"
        },
        {
          "name": "Hydroxychloroquine",
          "type": "DRUG"
        },
        {
          "name": "Hydroxychloroquine + lopinavir/ritonavir",
          "type": "DRUG"
        },
        {
          "name": "Ivermectin",
          "type": "DRUG"
        },
        {
          "name": "No immune modulation for COVID-19",
          "type": "OTHER"
        },
        {
          "name": "Interferon beta-1a",
          "type": "DRUG"
        },
        {
          "name": "Anakinra",
          "type": "DRUG"
        },
        {
          "name": "Tocilizumab",
          "type": "DRUG"
        },
        {
          "name": "Sarilumab",
          "type": "DRUG"
        },
        {
          "name": "Local standard venous thromboprophylaxis",
          "type": "DRUG"
        },
        {
          "name": "Therapeutic dose anticoagulation",
          "type": "DRUG"
        },
        {
          "name": "Conventional low dose thromboprophylaxis",
          "type": "DRUG"
        },
        {
          "name": "Intermediate dose thromboprophylaxis",
          "type": "DRUG"
        },
        {
          "name": "Continuation of therapeutic dose anticoagulation",
          "type": "DRUG"
        },
        {
          "name": "No immunoglobulin",
          "type": "OTHER"
        },
        {
          "name": "Convalescent plasma",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Delayed administration of convalescent plasma",
          "type": "BIOLOGICAL"
        },
        {
          "name": "No vitamin C",
          "type": "OTHER"
        },
        {
          "name": "Vitamin C",
          "type": "DRUG"
        },
        {
          "name": "No antiplatelet",
          "type": "OTHER"
        },
        {
          "name": "Aspirin",
          "type": "DRUG"
        },
        {
          "name": "P2Y12 inhibitor",
          "type": "DRUG"
        },
        {
          "name": "No simvastatin",
          "type": "OTHER"
        },
        {
          "name": "Simvastatin",
          "type": "DRUG"
        },
        {
          "name": "Eritoran",
          "type": "DRUG"
        },
        {
          "name": "Apremilast",
          "type": "DRUG"
        },
        {
          "name": "Clinician-preferred mechanical ventilation strategy",
          "type": "PROCEDURE"
        },
        {
          "name": "Protocolised mechanical ventilation strategy",
          "type": "PROCEDURE"
        },
        {
          "name": "No renin-angiotensin system inhibitor",
          "type": "OTHER"
        },
        {
          "name": "Angiotensin converting enzyme inhibitor",
          "type": "DRUG"
        },
        {
          "name": "Angiotensin Receptor Blockers",
          "type": "DRUG"
        },
        {
          "name": "ARB + DMX-200",
          "type": "DRUG"
        },
        {
          "name": "No cysteamine",
          "type": "OTHER"
        },
        {
          "name": "Cysteamine",
          "type": "DRUG"
        },
        {
          "name": "Fixed-duration dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "Baloxavir Marboxil",
          "type": "DRUG"
        },
        {
          "name": "Five-days oseltamivir + baloxavir marboxil",
          "type": "DRUG"
        },
        {
          "name": "Ten-days oseltamivir + baloxavir marboxil",
          "type": "DRUG"
        },
        {
          "name": "No endothelial modulator",
          "type": "OTHER"
        },
        {
          "name": "Imatinib",
          "type": "DRUG"
        },
        {
          "name": "No Immune Modulator for Influenza",
          "type": "OTHER"
        },
        {
          "name": "Baricitinib",
          "type": "DRUG"
        },
        {
          "name": "Nirmatrelvir/ritonavir",
          "type": "DRUG"
        },
        {
          "name": "Remdesivir",
          "type": "DRUG"
        },
        {
          "name": "Nirmatrelvir/ritonavir + remdesivir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "BIOLOGICAL",
        "PROCEDURE"
      ],
      "sponsor": "UMC Utrecht",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20000,
      "start_date": "2016-04-11",
      "completion_date": "2028-02",
      "has_results": false,
      "last_update_posted_date": "2024-07-12",
      "last_synced_at": "2026-10-27T16:52:23.740Z",
      "location_count": 11,
      "location_summary": "Jacksonville, Florida • Augusta, Georgia • Chicago, Illinois + 8 more",
      "locations": [
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02735707"
    },
    {
      "nct_id": "NCT02787551",
      "title": "Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Insulin glargine/lixisenatide fixed ratio combination",
          "type": "DRUG"
        },
        {
          "name": "liraglutide",
          "type": "DRUG"
        },
        {
          "name": "exenatide",
          "type": "DRUG"
        },
        {
          "name": "exenatide extended-release",
          "type": "DRUG"
        },
        {
          "name": "albiglutide",
          "type": "DRUG"
        },
        {
          "name": "dulaglutide",
          "type": "DRUG"
        },
        {
          "name": "Background therapy: Oral Anti-diabetic Drug (Metformin, Pioglitazone, SGLT2 inhibitor)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 514,
      "start_date": "2016-07-06",
      "completion_date": "2018-11-17",
      "has_results": true,
      "last_update_posted_date": "2022-03-25",
      "last_synced_at": "2026-10-27T16:52:23.740Z",
      "location_count": 74,
      "location_summary": "Birmingham, Alabama • Fountain Hills, Arizona • Phoenix, Arizona + 62 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Fountain Hills",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02787551"
    },
    {
      "nct_id": "NCT01287130",
      "title": "AZD6244 With Cetuximab for Solid Tumors and Colorectal Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Colonic Neoplasms",
        "Cancer of the Colon",
        "Colon Cancer",
        "Colon Neoplasms",
        "Colonic Cancer"
      ],
      "interventions": [
        {
          "name": "Cetuximab",
          "type": "DRUG"
        },
        {
          "name": "AZD6244",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 10,
      "start_date": "2011-01-07",
      "completion_date": "2013-08-27",
      "has_results": false,
      "last_update_posted_date": "2019-12-17",
      "last_synced_at": "2026-10-27T16:52:23.740Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01287130"
    },
    {
      "nct_id": "NCT07201519",
      "title": "Study of Safety/Feasibility of a Hybrid Model of Tertiary and Community Delivery of Hepatic Artery Infusion Chemotherapy",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Colorectal Cancer Metastatic",
        "Intrahepatic Cholangiocarcinoma"
      ],
      "interventions": [
        {
          "name": "Hepatic Artery Infusion Pump (HAIP)",
          "type": "DEVICE"
        },
        {
          "name": "Standard Treatment",
          "type": "PROCEDURE"
        },
        {
          "name": "Community Treatment",
          "type": "PROCEDURE"
        },
        {
          "name": "Systemic Chemotherapy Standard of Care",
          "type": "DRUG"
        },
        {
          "name": "Standard Of Care targeting driver mutations",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "Michael J Cavnar, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 80,
      "start_date": "2026-01-23",
      "completion_date": "2030-02",
      "has_results": false,
      "last_update_posted_date": "2026-02-04",
      "last_synced_at": "2026-10-27T16:52:23.740Z",
      "location_count": 1,
      "location_summary": "Lexington, Kentucky",
      "locations": [
        {
          "city": "Lexington",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07201519"
    },
    {
      "nct_id": "NCT04892017",
      "title": "Study of Inlexisertib (DCC-3116) in Participants With RAS/MAPK Pathway Mutant Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer",
        "Advanced Solid Tumor",
        "Metastatic Solid Tumor"
      ],
      "interventions": [
        {
          "name": "Inlexisertib",
          "type": "DRUG"
        },
        {
          "name": "Trametinib",
          "type": "DRUG"
        },
        {
          "name": "Binimetinib",
          "type": "DRUG"
        },
        {
          "name": "Sotorasib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Deciphera Pharmaceuticals, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 91,
      "start_date": "2021-06-15",
      "completion_date": "2026-03-30",
      "has_results": false,
      "last_update_posted_date": "2026-04-08",
      "last_synced_at": "2026-10-27T16:52:23.740Z",
      "location_count": 10,
      "location_summary": "Boston, Massachusetts • St Louis, Missouri • New Brunswick, New Jersey + 7 more",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04892017"
    },
    {
      "nct_id": "NCT06589596",
      "title": "An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumor"
      ],
      "interventions": [
        {
          "name": "BGB-58067",
          "type": "DRUG"
        },
        {
          "name": "BG-89894",
          "type": "DRUG"
        },
        {
          "name": "Standard of Care Therapy",
          "type": "DRUG"
        },
        {
          "name": "RAS(ON) Inhibitors",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "BeOne Medicines",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 695,
      "start_date": "2025-01-10",
      "completion_date": "2028-08-31",
      "has_results": false,
      "last_update_posted_date": "2026-10-20",
      "last_synced_at": "2026-10-27T16:52:23.740Z",
      "location_count": 12,
      "location_summary": "Los Alamitos, California • Los Angeles, California • Celebration, Florida + 8 more",
      "locations": [
        {
          "city": "Los Alamitos",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Celebration",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06589596"
    },
    {
      "nct_id": "NCT06445062",
      "title": "Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Colorectal Cancer",
        "CRC",
        "Pancreatic Ductal Adenocarcinoma",
        "PDAC",
        "Gastrointestinal Cancer",
        "Metastatic Pancreatic Ductal Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "RMC-6236",
          "type": "DRUG"
        },
        {
          "name": "mFOLFOX6 regimen",
          "type": "DRUG"
        },
        {
          "name": "bevacizumab",
          "type": "DRUG"
        },
        {
          "name": "mFOLFIRINOX regimen",
          "type": "DRUG"
        },
        {
          "name": "cetuximab",
          "type": "DRUG"
        },
        {
          "name": "gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "nab-paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "RMC-9805",
          "type": "DRUG"
        },
        {
          "name": "FOLFIRI regimen",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Revolution Medicines, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1130,
      "start_date": "2024-05-24",
      "completion_date": "2030-03-30",
      "has_results": false,
      "last_update_posted_date": "2026-09-22",
      "last_synced_at": "2026-10-27T16:52:23.740Z",
      "location_count": 32,
      "location_summary": "Chandler, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 24 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06445062"
    },
    {
      "nct_id": "NCT07325435",
      "title": "Beta Cell Function in Type 2 Diabetes: Differential Effects of SGLT2 Inhibitors and GLIP-Receptor Agonists",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Type 2 Diabetes (T2DM)"
      ],
      "interventions": [
        {
          "name": "SGLT-2 inhibitor",
          "type": "DRUG"
        },
        {
          "name": "GLP1-RA",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "MaryAnn Banerji",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "24 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "24 Years to 80 Years"
      },
      "enrollment_count": 60,
      "start_date": "2024-12-21",
      "completion_date": "2028-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-01-08",
      "last_synced_at": "2026-10-27T16:52:23.740Z",
      "location_count": 1,
      "location_summary": "Brooklyn, New York",
      "locations": [
        {
          "city": "Brooklyn",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07325435"
    },
    {
      "nct_id": "NCT06162221",
      "title": "Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer, NSCLC",
        "KRAS, NRAS, HRAS-mutated NSCLC",
        "KRAS G12C-mutated Solid Tumors, Lung Cancer",
        "Lung Cancer Stage IV, Advanced Solid Tumor, Cancer",
        "RAS G12D-mutated NSCLC"
      ],
      "interventions": [
        {
          "name": "RMC-6291",
          "type": "DRUG"
        },
        {
          "name": "RMC-6236",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Pemetrexed",
          "type": "DRUG"
        },
        {
          "name": "RMC-9805",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Revolution Medicines, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 616,
      "start_date": "2024-01-18",
      "completion_date": "2028-12",
      "has_results": false,
      "last_update_posted_date": "2026-10-19",
      "last_synced_at": "2026-10-27T16:52:23.740Z",
      "location_count": 29,
      "location_summary": "Gilbert, Arizona • Duarte, California • Irvine, California + 24 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06162221"
    }
  ]
}